Genentech is teaming up with Bicycle Therapeutics to develop cancer immunotherapies. Bicycle uses chemical scaffolds to turn linear peptides into two pretzel-like loops. The firm says these so-called bicyclic peptides can be used as drugs alone or to deliver toxic payloads to cancer cells. Bicycle has several cancer drug programs of its own. Genentech will pay Bicycle $30 million up front—and up to $1.7 billion in milestone payments—to develop bicyclic peptides against several new targets.
10.1021/cen-09809-buscon18-bicycle-gr1
Bicycle's bicyclic peptides can be linked to anticancer toxins. (Credit: Bicycle/C&EN)
Genentech strikes deal with Bicycle
Chemical & Engineering News ; 98 , 9 ; 25
2020-03-09
Article (Journal)
Electronic Resource
Unknown
Mesa Strikes Deal With GFI And Woodward
Online Contents | 1996
Outsourcing Zurich strikes GBP700m outsourcing deal with CSC
British Library Online Contents | 2004
EU gives Galileo green light . Alitalia strikes union cost cuts deal
Online Contents | 2002
Mesa to firm up Embraer orders . Chautauqua strikes deal with America West
Online Contents | 2001
Paris Show Report - USAF strikes Predator-Viper deal . Smiths to grow Chinese production
Online Contents | 2005